About vutrisiran
Transthyretin-directed small interfering RNA
Used for
- Treats hereditary transthyretin-mediated amyloidosis in adults with polyneuropathy.
- Treats cardiomyopathy caused by transthyretin-mediated amyloidosis in adults.
Usual adult dose
25 mg injected under the skin every 3 months.
Common side effects
- Pain, redness, or bruising at the injection site
- Joint pain
- Shortness of breath
- Low vitamin A levels
Important warnings
- Can lower vitamin A; supplementation and monitoring are needed.
- Avoid in people with serious hypersensitivity to vutrisiran or its ingredients.
- Effectiveness and safety in children are not established.
Pregnancy
Human pregnancy data are limited. Low vitamin A may harm fetal development; treatment requires careful assessment.
Breastfeeding
It is unknown whether vutrisiran enters breast milk or affects a nursing infant.
Interactions
- Vitamin A supplements can increase the risk of excessive vitamin A; dosing requires clinical monitoring.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.